Trial Profile
A phase II study to determine the safety and anti-leukemic effects of STI571 [imatinib] in adult patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leukemia, acute myeloid leukemia, lymphoid blast crisis chronic myeloid leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2006
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Leukaemia
- Focus Therapeutic Use
- 09 Jan 2006 New trial record.